Elke M. G. J. de Jong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elke M. G. J. de Jong has a total of 370 co-authors. Here are the top co-authors by number of shared publications:
- Juul M. P. A. van Den Reek
Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands
36 shared publications - Peter Cornelis Maria van de Kerkhof
Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands
10 shared publications - Hans Groenewoud
Department for Health Evidence Radboud University Nijmegen the Netherlands
9 shared publications - Marieke Martha Benedicta Seyger
Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands
7 shared publications - Satish Frank Kishore Lubeek
Department of Dermatology Radboud University Medical Center Nijmegen the Netherlands
7 shared publications - Marisol E. Otero
Department of Dermatology, Radboud University Medical Center
6 shared publications
Latest Publications
- Open Access
- 3 October 2026
- Published by Elsevier in JID Innovations
- Vol. 7 (1)
A survival guide for drug survival studies in dermatology: Methodological approaches and best practices
- 3 October 2026
- Published by Elsevier in JID Innovations
- Vol. 7 (1)
Open AccessA survival guide for drug survival studies in dermatology: Methodological approaches and best practices
- Open Access
- 9 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9)
Future Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers
Successful implementation of dermatological biomarkers depends on early understanding of clinical needs and adoption barriers. Yet, research on these factors as perceived by dermatological care providers (DCPs) is scarce and perspectives of patients are largely underexplored. This survey study among patients and DCPs assessed biomarker needs and adoption barriers and facilitators for five inflammatory skin diseases: psoriasis (PsO), atopic dermatitis (AD), hidradenitis suppurativa (HS), cutaneous lupus erythematosus (CLE) and chronic spontaneous urticaria (CSU). In total, the study population consisted of 591 patients and 99 DCPs. Across all skin diseases, both groups mainly prioritized a biomarker for prediction of therapeutic response, however, DCPs prioritized this substantially more often than patients, especially for PsO (79.8% vs. 31.3% resp.), AD (68.7% vs. 37.1% resp.) and HS (66.7% vs. 34.4% resp.). Notably, a biomarker for the prediction of the risk to develop comorbidities was prioritized relatively often by patients (7.0%–19.4%), whereas DCPs only substantially prioritized this for CLE (14.1%). To enhance implementation, patients must ideally be able to undergo biomarker collection nearby their homes (travel time < 1 h) with complete reimbursement. For DCPs it is important that the biomarker is well validated, non‐invasive and measurable during regular visits with preferably a short sampling time.
- 9 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9)
Open AccessFuture Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers
Successful implementation of dermatological biomarkers depends on early understanding of clinical needs and adoption barriers. Yet, research on these factors as perceived by dermatological care providers (DCPs) is scarce and perspectives of patients are largely underexplored. This survey study among patients and DCPs assessed biomarker needs and adoption barriers and facilitators for five inflammatory skin diseases: psoriasis (PsO), atopic dermatitis (AD), hidradenitis suppurativa (HS), cutaneous lupus erythematosus (CLE) and chronic spontaneous urticaria (CSU). In total, the study population consisted of 591 patients and 99 DCPs. Across all skin diseases, both groups mainly prioritized a biomarker for prediction of therapeutic response, however, DCPs prioritized this substantially more often than patients, especially for PsO (79.8% vs. 31.3% resp.), AD (68.7% vs. 37.1% resp.) and HS (66.7% vs. 34.4% resp.). Notably, a biomarker for the prediction of the risk to develop comorbidities was prioritized relatively often by patients (7.0%–19.4%), whereas DCPs only substantially prioritized this for CLE (14.1%). To enhance implementation, patients must ideally be able to undergo biomarker collection nearby their homes (travel time < 1 h) with complete reimbursement. For DCPs it is important that the biomarker is well validated, non‐invasive and measurable during regular visits with preferably a short sampling time.
- Open Access
- 10 August 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1)
Patients’ and clinicians’ perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis - a mixed methods study
Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases, and due to the chronic nature of these diseases lifelong treatment is often required. In many countries, patients with ps...
- 10 August 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1)
Open AccessPatients’ and clinicians’ perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis - a mixed methods study
Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases, and due to the chronic nature of these diseases lifelong treatment is often required. In many countries, patients with ps...
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 16, 1-11
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study
Psoriasis extends beyond skin manifestations and significantly impacts patients’ psychological health, social interactions, and daily functioning. The main objective was to assess the 2-year effect of tildrakizumab, an interleukin-23p19 inhibitor, on the skin, the psychological well-being and the health-related quality of life (HRQoL) of people with psoriatic disease in real-world. The POSITIVE study is a 24-month, prospective observational multinational study enrolling adults with moderate-to-severe plaque psoriasis treated with tildrakizumab according to clinical practice. Outcome measurements included the 5-item WHO Well-being Index (WHO-5), Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index-Relevant (DLQI-R). 785 patients were included. The mean (95% CI) WHO-5 score increased from 53.7 (52.2, 55.3) at baseline to 63.2 (61.5, 64.8) at W16 and continued improving over time: 65.9 (64.0, 67.9) at W52 and 70.4 (68.1, 72.7) at W104. The mean (95% CI) PASI decreased from 12.9 (12.3, 13.5) at baseline to 2.4 (2.2, 2.7) at W16 and was maintained until W104 [1.3 (1.1, 1.5)]. At W104, 87.9/79.0/65.1% of patients maintained PASI ≤3/≤2/≤1. Drug survival due to lack of effectiveness or adverse events (AE) was 87.8% and 96.3% after 2 years. The mean (95% CI) DLQI-R score decreased from 12.0 (11.4, 12.6) at baseline to 3.1 (2.6, 3.6) W52 and 2.1 (1.7, 2.5) at W104. At the final analysis, 11.1% of patients had ≥1 related AE. Treatment with tildrakizumab delivered sustained and holistic long-term health for moderate to severe psoriasis over 2 years by consistently improving patients’ psychological well-being, life and clinical outcomes with a favourable safety profile. NCT04823247
- 1 May 2026
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 16, 1-11
Open AccessPatient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study
Psoriasis extends beyond skin manifestations and significantly impacts patients’ psychological health, social interactions, and daily functioning. The main objective was to assess the 2-year effect of tildrakizumab, an interleukin-23p19 inhibitor, on the skin, the psychological well-being and the health-related quality of life (HRQoL) of people with psoriatic disease in real-world. The POSITIVE study is a 24-month, prospective observational multinational study enrolling adults with moderate-to-severe plaque psoriasis treated with tildrakizumab according to clinical practice. Outcome measurements included the 5-item WHO Well-being Index (WHO-5), Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index-Relevant (DLQI-R). 785 patients were included. The mean (95% CI) WHO-5 score increased from 53.7 (52.2, 55.3) at baseline to 63.2 (61.5, 64.8) at W16 and continued improving over time: 65.9 (64.0, 67.9) at W52 and 70.4 (68.1, 72.7) at W104. The mean (95% CI) PASI decreased from 12.9 (12.3, 13.5) at baseline to 2.4 (2.2, 2.7) at W16 and was maintained until W104 [1.3 (1.1, 1.5)]. At W104, 87.9/79.0/65.1% of patients maintained PASI ≤3/≤2/≤1. Drug survival due to lack of effectiveness or adverse events (AE) was 87.8% and 96.3% after 2 years. The mean (95% CI) DLQI-R score decreased from 12.0 (11.4, 12.6) at baseline to 3.1 (2.6, 3.6) W52 and 2.1 (1.7, 2.5) at W104. At the final analysis, 11.1% of patients had ≥1 related AE. Treatment with tildrakizumab delivered sustained and holistic long-term health for moderate to severe psoriasis over 2 years by consistently improving patients’ psychological well-being, life and clinical outcomes with a favourable safety profile. NCT04823247
- Open Access
- 21 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (9) , 1449-1459
International consensus on dose reduction of biologics for patients with psoriasis: The DR . Delphi study
Background: Dose reduction (DR) of biologics for psoriasis is already applied in clinical practice but without clear guidelines, while dermatologists addressed the need for guidance. An international consensus may contribute to optimal implementation of biologic DR in clinical psoriasis practices. Objectives: This consensus study aims for international consensus on DR of biologics in adult patients with psoriasis among dermatologists worldwide. Methods: An international, modified eDelphi consensus study was performed among dermatologists worldwide. A total of 11 statements on biologic DR were generated by the international steering committee, based on a previous literature review. Invitations were distributed via international dermatological societies. Participants rated their level of agreement per statement on a 9‐point Likert scale. A maximum of three consensus rounds and one (digital) consensus meeting were expected. Statements reached consensus if ≥70% agreed and <15% disagreed; otherwise, statements were revised for a next consensus round. Results: In total, 62 dermatologists from Europe, South America, Asia, North America, Africa and Australia completed the eDelphi. After one round, 9 out of 11 statements reached consensus. The remaining 2 statements were adapted and reached consensus in the second round. Participants agreed on criteria when to consider and initiate/(dis)continue DR and on a two‐step DR algorithm for adalimumab, etanercept and ustekinumab. Participants agreed that this two‐step DR strategy can also be considered for IL‐17 and IL‐23 inhibitors while awaiting more scientific evidence on DR of these newer biologics. Conclusions: Dermatologists worldwide reached consensus on when and how to initiate and (dis)continue DR of biologics, and on a two‐step DR algorithm for adalimumab, etanercept and ustekinumab in adult patients with psoriasis. DR of IL‐17 and IL‐23 inhibitors was deemed feasible; however, underlying evidence is still limited. This first international consensus provides essential information for uptake and implementation of biologic DR for psoriasis on a global scale.
- 21 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (9) , 1449-1459
Open AccessInternational consensus on dose reduction of biologics for patients with psoriasis: The DR . Delphi study
Background: Dose reduction (DR) of biologics for psoriasis is already applied in clinical practice but without clear guidelines, while dermatologists addressed the need for guidance. An international consensus may contribute to optimal implementation of biologic DR in clinical psoriasis practices. Objectives: This consensus study aims for international consensus on DR of biologics in adult patients with psoriasis among dermatologists worldwide. Methods: An international, modified eDelphi consensus study was performed among dermatologists worldwide. A total of 11 statements on biologic DR were generated by the international steering committee, based on a previous literature review. Invitations were distributed via international dermatological societies. Participants rated their level of agreement per statement on a 9‐point Likert scale. A maximum of three consensus rounds and one (digital) consensus meeting were expected. Statements reached consensus if ≥70% agreed and <15% disagreed; otherwise, statements were revised for a next consensus round. Results: In total, 62 dermatologists from Europe, South America, Asia, North America, Africa and Australia completed the eDelphi. After one round, 9 out of 11 statements reached consensus. The remaining 2 statements were adapted and reached consensus in the second round. Participants agreed on criteria when to consider and initiate/(dis)continue DR and on a two‐step DR algorithm for adalimumab, etanercept and ustekinumab. Participants agreed that this two‐step DR strategy can also be considered for IL‐17 and IL‐23 inhibitors while awaiting more scientific evidence on DR of these newer biologics. Conclusions: Dermatologists worldwide reached consensus on when and how to initiate and (dis)continue DR of biologics, and on a two‐step DR algorithm for adalimumab, etanercept and ustekinumab in adult patients with psoriasis. DR of IL‐17 and IL‐23 inhibitors was deemed feasible; however, underlying evidence is still limited. This first international consensus provides essential information for uptake and implementation of biologic DR for psoriasis on a global scale.
- Open Access
- 1 April 2026
- Published by Elsevier in SSRN Electronic Journal
Functional Immune Phospho-Flow Profiling of the JAK–STAT Pathway To Guide JAK-Inhibitor Therapy
Background: The Janus kinase–signal transducer and activator of transcription (JAK/STAT) pathway regulates key cellular processes. Dysregulation of this pathway can lead to chronic immune activation. Although JAK inhibitors are promising, cytokine-specific STAT activation and JAK inhibitor modulation remain poorly understood. To address this knowledge gap, we developed a phospho-flow-based JAK/STAT assay and demonstrated its potential for precision medicine. We illustrate its application using three clinical case studies. Methods: Peripheral blood mononuclear cells (PBMCs) and biopsy-derived single cell suspensions of inflamed and uninflamed tissues were stimulated with either individual cytokines (IL-4, IL-6, IL-7, IL-13 or IFN-α) or a cytokine mixture. The phosphorylation of STAT1, STAT3, STAT5 and STAT6 was quantified by flow cytometry across multiple immune cell subsets. For JAK inhibition studies, PBMCs from healthy controls and patients, and tissue biopsies from patients, were incubated with JAK inhibitors prior to cytokine stimulation. Findings: Cytokines induced phosphorylation of distinct STAT proteins across multiple immune cell subsets. In addition, JAK inhibitors exhibited differential potency across these subsets, resulting in variable modulation of STAT phosphorylation. Guided by these functional readouts, patients received specific JAK inhibitors, resulting in clinical improvement. In two atopic dermatitis patients treated with a JAK1 inhibitor, stimulation-induced STAT1 phosphorylation decreased in the responder but increased in the non-responder. Interpretation: We developed a JAK/STAT assay enabling immune cell subset-specific analysis in both blood- and tissue-derived immune cells. This approach revealed disease-associated signaling abnormalities and differential JAK-inhibitor responses, supporting therapeutic decision-making and precision medicine in immune-mediated diseases.
- 1 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFunctional Immune Phospho-Flow Profiling of the JAK–STAT Pathway To Guide JAK-Inhibitor Therapy
Background: The Janus kinase–signal transducer and activator of transcription (JAK/STAT) pathway regulates key cellular processes. Dysregulation of this pathway can lead to chronic immune activation. Although JAK inhibitors are promising, cytokine-specific STAT activation and JAK inhibitor modulation remain poorly understood. To address this knowledge gap, we developed a phospho-flow-based JAK/STAT assay and demonstrated its potential for precision medicine. We illustrate its application using three clinical case studies. Methods: Peripheral blood mononuclear cells (PBMCs) and biopsy-derived single cell suspensions of inflamed and uninflamed tissues were stimulated with either individual cytokines (IL-4, IL-6, IL-7, IL-13 or IFN-α) or a cytokine mixture. The phosphorylation of STAT1, STAT3, STAT5 and STAT6 was quantified by flow cytometry across multiple immune cell subsets. For JAK inhibition studies, PBMCs from healthy controls and patients, and tissue biopsies from patients, were incubated with JAK inhibitors prior to cytokine stimulation. Findings: Cytokines induced phosphorylation of distinct STAT proteins across multiple immune cell subsets. In addition, JAK inhibitors exhibited differential potency across these subsets, resulting in variable modulation of STAT phosphorylation. Guided by these functional readouts, patients received specific JAK inhibitors, resulting in clinical improvement. In two atopic dermatitis patients treated with a JAK1 inhibitor, stimulation-induced STAT1 phosphorylation decreased in the responder but increased in the non-responder. Interpretation: We developed a JAK/STAT assay enabling immune cell subset-specific analysis in both blood- and tissue-derived immune cells. This approach revealed disease-associated signaling abnormalities and differential JAK-inhibitor responses, supporting therapeutic decision-making and precision medicine in immune-mediated diseases.
- 2 December 2025
- Published by Springer Nature in European Geriatric Medicine
- Vol. 17 (1) , 365-390
Impact of interprofessional collaboration between long-term care physicians and medical specialists on quality of care and quality of life of long-term care facility residents: a systematic review
Key summary points AbstractSection Aim The main aim of this study is to identify the impact of interprofessional collaboration interventions between long-term care (LTC) physicians and medical specialists on the quality of life (QoL) and quality of care (QoC) of long-term care facility (LTCF) residents in need of medical specialist’s expertise. AbstractSection Findings Three ways of interprofessional collaboration between LTC physicians and medical specialists were identified: teleconsultations, on-site consultation services, and multidisciplinary collaboration interventions. Most interprofessional collaboration interventions indicated a positive impact on LTCF residents’ QoL or QoC. AbstractSection Message Whereas teleconsultations eliminate residents’ travel burden, may reduce costs and support triage decisions, on-site consultation services remain essential when remote assessment is inadequate. Multidisciplinary collaboration interventions, combining tele- and on-site consultations with additional elements and support, demonstrate promising sustainable and positive impact on LTCF residents’ QoL and QoC.
- 2 December 2025
- Published by Springer Nature in European Geriatric Medicine
- Vol. 17 (1) , 365-390
Impact of interprofessional collaboration between long-term care physicians and medical specialists on quality of care and quality of life of long-term care facility residents: a systematic review
Key summary points AbstractSection Aim The main aim of this study is to identify the impact of interprofessional collaboration interventions between long-term care (LTC) physicians and medical specialists on the quality of life (QoL) and quality of care (QoC) of long-term care facility (LTCF) residents in need of medical specialist’s expertise. AbstractSection Findings Three ways of interprofessional collaboration between LTC physicians and medical specialists were identified: teleconsultations, on-site consultation services, and multidisciplinary collaboration interventions. Most interprofessional collaboration interventions indicated a positive impact on LTCF residents’ QoL or QoC. AbstractSection Message Whereas teleconsultations eliminate residents’ travel burden, may reduce costs and support triage decisions, on-site consultation services remain essential when remote assessment is inadequate. Multidisciplinary collaboration interventions, combining tele- and on-site consultations with additional elements and support, demonstrate promising sustainable and positive impact on LTCF residents’ QoL and QoC.
- Open Access
- 30 July 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2532676
Family planning and pregnancy among patients with psoriasis: incorporating the patients’ voice in healthcare practice and information provision
Aim: Having psoriasis and being treated with medication could raise concerns regarding family planning and pregnancy (FPP), and no guidelines are available on healthcare practice and information provision regarding FPP for these patients. This study aims to gain insight in the perspectives of patients with psoriasis on this important subject. Methods: A cross-sectional questionnaire study including adult female and male patients with psoriasis, independent of their treatment type. Results: A total of 102 patients responded to the questionnaire (70% females, 30% males), of whom 47.1% have ever used biologic therapy. Respondents preferred dermatologists or general practitioners (GPs) as information provider. Patients would like to receive FPP information on fertility, heredity of psoriasis, use of psoriasis medication, and - specifically for females- the course of psoriasis during and after pregnancy and breastfeeding. Timing of FPP information provision was preferable at moment of diagnosis and medication changes or upon explicit request. Conclusion: Dermatologists and GPs have a crucial role in providing FPP information. The findings of this study have provided hands-on guidance for healthcare professionals to improve healthcare for both female and male patients with psoriasis in the reproductive age.
- 30 July 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2532676
Open AccessFamily planning and pregnancy among patients with psoriasis: incorporating the patients’ voice in healthcare practice and information provision
Aim: Having psoriasis and being treated with medication could raise concerns regarding family planning and pregnancy (FPP), and no guidelines are available on healthcare practice and information provision regarding FPP for these patients. This study aims to gain insight in the perspectives of patients with psoriasis on this important subject. Methods: A cross-sectional questionnaire study including adult female and male patients with psoriasis, independent of their treatment type. Results: A total of 102 patients responded to the questionnaire (70% females, 30% males), of whom 47.1% have ever used biologic therapy. Respondents preferred dermatologists or general practitioners (GPs) as information provider. Patients would like to receive FPP information on fertility, heredity of psoriasis, use of psoriasis medication, and - specifically for females- the course of psoriasis during and after pregnancy and breastfeeding. Timing of FPP information provision was preferable at moment of diagnosis and medication changes or upon explicit request. Conclusion: Dermatologists and GPs have a crucial role in providing FPP information. The findings of this study have provided hands-on guidance for healthcare professionals to improve healthcare for both female and male patients with psoriasis in the reproductive age.
- Open Access
- 23 July 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2532672
Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity
Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study. Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children's) Dermatology Life Quality Index ((C)DLQI) scores between sexes. We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males. Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.
- 23 July 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2532672
Open AccessSex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity
Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study. Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children's) Dermatology Life Quality Index ((C)DLQI) scores between sexes. We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males. Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.